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Activated STAT1 suppresses proliferation of cultured rat mes- ated with proliferation of lymphopoietic and hematopoi-
angial cells. etic lineages by themselves or in concert with other signal
Background. JAK-STAT signaling has been shown to pro- transduction pathways [3–6]. Erythropoietin, a cyto-mote development and proliferation in lymphopoietic and he-
kine that stimulates erythropoiesis, induces associationmatopoietic lineages. We investigated the effect of activated
of JAK2 with erythropoietin receptor [7–10]. Platelet-STAT1 on mesangial cell proliferation.
Methods. Rat mesangial cells of primary culture (rMCs) derived growth factor (PDGF) induces proliferation of
were used in the following experiments: (1) Whole cell lysates vascular smooth muscle cells via activated JAK2 in con-
were immunoblotted against JAK1 and JAK2. (2) Whole cell cert with mitogen-activated protein (MAP) kinase cas-lysates and nuclear proteins were extracted from rMCs with
cades [11]. PDGF receptor stimulates tyrosine phosphor-or without treatment with interferon-g, and immunoblotting
ylation of JAK1 [12], and in addition to this pathway,was performed against both STAT1 and tyrosine (701)-phos-
phorylated STAT1. (3) rMCs and rMCs electroporated with the receptor itself can also directly phosphorylate and
either wild-type STAT1, mutated STAT1, or antibody against activate STAT1 in a JAK-independent way [13, 14]. An-
STAT1 were incubated with interferon-g for 20 hours, followed
giotensin II stimulates tyrosine phosphorylation of JAK2by a further incubation with [3H]-thymidine for four hours.
and Tyk2 via type I angiotensin II receptor, which, inResults. JAK1, JAK2, and STAT1 were detected in whole
cell lysates, suggesting that JAK-STAT signaling could be acti- turn, activates STAT1, STAT2, and STAT3 and induces
vated by interferon-g (INF-g). Using an antibody specific for a cellular proliferative response in vascular smooth mus-
tyrosine-phosphorylated STAT1, we detected signal in the cle cells [15]. The inactivation of intracellular STAT1 or
INF-g–treated nuclear extracts, which showed translocation of
STAT3 abolishes the proliferative effect of angiotensinphosphorylated STAT1 to the nucleus. [3H]-thymidine incorpo-
II [11, 16, 17].ration in the presence of INF-g was significantly lower than that
of control in a dose-dependent manner. The introduction of wild- On the other hand, growth inhibition induced by epi-
type STAT1 enhanced the effect of interferon-g and decreased dermal growth factor, interferon-a (IFN-a), and IFN-g
[3H]-thymidine incorporation, whereas tyrosine-mutated (Y701F) requires STAT1 activation [18–20], and antiproliferative
STAT1 and SH2 domain (R602T)-mutated STAT1 reversed
activity of IFN-g is enhanced by prolonged activation ofINF-g–induced suppression of [3H]-thymidine incorporation.
STAT1 [21]. Thus, it remains to be determined whetherElectroinjected antibody against STAT1 increased [3H]-thymi-
activated STAT1 has a proliferative or an antiprolifera-dine incorporation upon stimulation with INF-g.
Conclusion. STAT1 activated by interferon-g suppresses tive effect. Mesangial cell proliferation causes the de-
mesangial cell proliferation. struction of glomerular architecture in chronic glomeru-
lonephritis, thereby leading to a loss of renal function.
PDGF is well known to be a major candidate for mesan-
There is growing evidence that Janus kinases (JAKs), gial cell proliferation in chronic glomerulonephritis [22],
especially JAK2 [1, 2], and signal transducers and activa- and angiotensin II may be associated with benign neph-
tors of transcription (STAT) pathways are closely associ- rosclerosis. In both cases, the signaling converges to
STAT1 activation. PDGF activates not only STAT1, but
also the MAP kinase cascade at the same time [11].Key words: Janus kinases, mesangial cells, interferon-g, cell prolifera-
tion, signal transduction. Thus, it is not clear whether STAT1 further accelerates
mesangial cell proliferation in concert with MAP kinases,Received for publication April 12, 1999
or STAT1 modulates and counteracts the proliferativeand in revised form December 11, 1999
Accepted for publication January 7, 2000 effect of MAP kinases. The need to better understand
the molecular basis for mesangial proliferative glomeru-Ó 2000 by the International Society of Nephrology
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lonephritis is strong motivation for us to determine the mmol/L HEPES, pH 7.5, 250 mmol/L KCl, 0.1 mmol/L
ethylenediaminetetraacetic acid (EDTA), 0.1 mmol/L eg-precise role of STAT1.
Interferon-g activation of JAK1 and JAK2 induces tazic acid (EGTA), 10% glycerol, 0.1% NP-40, 0.5 mmol/L
phenylmethylsulfonyl fluoride (PMSF), 0.5 mmol/L dithio-phosphorylation of STAT1 tyrosine residue (701) and
formation of active homodimer, leading to nuclear trans- threitol (DTT), 1 mg/mL aprotinin, and 1 mg/mL pep-
statin A]. The cell suspension was vortexed vigorouslylocation and DNA binding [23, 24]. Since the IFN-g–
activated signaling pathway involving STAT1 is simpler on a platform with medium rotation for 30 minutes and
centrifuged at 15000 r.p.m. for 30 minutes. The proteinand more straightforward than other cytokines, and the
signaling pathways of several growth factors converge concentration of the supernatants was determined by
colorimetric assay [26].to STAT1 in combination with the other signalings, we
employed IFN-g to stimulate the JAK-STAT pathway
Preparation of nuclear extractsin this study. We investigated the effect of STAT1 acti-
vated by IFN-g on mesangial cell proliferation and found Nuclear extracts were prepared as described pre-
viously [27] with minor modification. Briefly, rMCs werethat IFN-g–suppressed [3H]-thymidine incorporation was
enhanced in the presence of transfected wild-type STAT1 harvested with trypsin and spun down. After resus-
pending the cell pellets in 400 mL of ice-cold Buffer Aand reversed by dominant-negative STAT1 (Y701F or
R602T). Electroinjected antibody against STAT1 in- (10 mmol/L HEPES, pH 7.9, 10 mmol/L KCl, 1 mmol/L
DTT, and 0.5 mmol/L PMSF), 25 mL of 10% Nonidetcreased IFN-g–suppressed [3H]-thymidine incorporation.
Our data suggest the growth-inhibitory role of activated P-40 solution were added, and the tube was vigorously
shaken on an orbital shaker for 30 seconds and centri-STAT1 in mesangial proliferative glomerulonephritis.
fuged for 30 seconds in a microfuge. Nuclear pellets were
resuspended in 100 mL of ice-cold Buffer C (20 mmol/L
METHODS
HEPES, pH 7.9, 400 mmol/L NaCl, 1 mmol/L EDTA,
Reagents 1 mmol/L EGTA, 1 mmol/L DTT, 1 mmol/L PMSF,
1 mg/mL aprotinin, and 1 mg/mL pepstatin A) and vigor-Mouse recombinant IFN-g was purchased from Sigma
Chemical (St. Louis, MO, USA). Rabbit polyclonal anti- ously rocked at 48C for 15 minutes on a shaking platform.
After centrifugation for 10 minutes at 48C, supernatantsbody directed against phosphorylated tyrosine (Tyr) (701)-
specific STAT1 was from New England Biolabs (Beverly, were collected. The protein concentration was deter-
mined by colorimetric assay [26].MA, USA). Mouse monoclonal antibody against STAT1
exclusively for electroinjection experiment and rabbit
Western blottingpolyclonal antibodies against JAK1, JAK2, and STAT1
were from Santa Cruz Biotechnology (Santa Cruz, CA, Whole cell lysates or nuclear extracts (10 mg of each)
were electrophoresed on the polyacrylamide gel. AfterUSA). Blocking peptides for JAK1, JAK2, and STAT1
were from Santa Cruz Biotechnology. [3H]-labeled thy- transfer to a polyvinylidene difluoride (PVDF) mem-
brane, the blocking procedure was performed with 5%midine and the ECL kit for Western blotting detection
reagents were purchased from Amersham (Buckingham- nonfat milk, and the membrane was incubated with anti-
body directed against either JAK1, JAK2, STAT1, orshire, UK). The b-galactosidase Enzyme Assay System
and horseradish peroxidase-conjugated goat antimouse tyrosine (701)-phosphorylated STAT1. Blocking pep-
tides for JAK1, JAK2, and STAT1 were incubated withIgG and antirabbit IgG were from Promega (Madison,
WI, USA). respective antibodies for two hours at 48C. After washing
the membranes, peroxidase-conjugated secondary anti-
Cell culture body was applied, and the protein of interest was identi-
fied by enhanced chemiluminescence (ECL kit) ac-Rat mesangial cells of primary culture (rMCs) were
derived from isolated rat glomeruli as previously de- cording to manufacturer’s instructions.
scribed [25]. Briefly, glomeruli obtained from renal corti-
Construction of expression vectorsces of Sprague-Dawley rats by sequential sieving were
resuspended in RPMI 1640 medium buffered with 20 cDNA for human STAT1 (a gift from Dr. James N.
Ihle) was subcloned into the pXM expression vector.mmol/L HEPES and were supplemented with 20% fetal
calf serum (FCS), 100 U/mL penicillin, and 100 mg/mL To generate point mutants for SH2 domain or tyrosine
residue, the arginine residue at 602 or the tyrosine resi-streptomycin. The glomeruli were cultured at 378C with
5% CO2. rMCs used were in early passage. due at 701 of STAT1 was replaced by threonine or phe-
nylalanine, respectively, using polymerase chain reaction
Preparation of whole cell lysates (PCR) with primers containing the appropriate muta-
tions, and then the mutants were confirmed by sequenc-Rat mesangial cells were harvested, pelleted by cen-
trifugation, and resuspended in 100 mL of lysis buffer [20 ing using autosequencer (Applied Biosystems, Chiba,
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Japan). These mutants were named R602T and Y701F, ylate STAT1. To determine whether this signaling path-
way also applied to rMCs, immunoblottings were per-respectively, according the amino acid number.
formed against JAK1, JAK2, and STAT1 (Fig. 1 A–C).
Transfection and transient expression of wild-type As nonspecific and confusing bands for JAK1, JAK2,
STAT1, tyrosine-mutated STAT1 (Y701F), and SH2 and STAT1 were present, blocking peptides were used
domain-mutated (R602T) cDNAs for each blotting. Compared with the usual immunoblot-
ting on each left panel, there was a band in the respectiveRat mesangial cells were harvested and centrifuged at
800 r.p.m. for five minutes. Cells were washed once in blotting on the right that disappeared when the antibody
incubated with blocking peptides was used. Therefore,Ca- and Mg-free phosphate-buffered saline (PBS) and
then resuspended in potassium-rich PBS. The cell sus- the bands for JAK1, JAK2, and STAT1 were confirmed,
respectively. We found that signal intensities of JAK1pension was put into an electroporation chamber with
empty vector or the plasmid containing cDNA for either and JAK2 in control were almost the same as those in
IFN-g and, furthermore, that STAT1 was localized inwild-type STAT1, tyrosine-mutated STAT1 (Y701F), or
SH2 domain-mutated STAT1 (R602T; 20 mg of each) cytosol under the untreated condition. In Figure 1, we
intended to show the existence of JAK1, JAK2, andand was then cotransfected with b-galactosidase expres-
sion plasmid (5 mg) by a single brief electric pulse with STAT1. The translocation of phosphorylated STAT1 in-
duced by IFN-g is demonstrated in Figure 2.a field strength of 750 V/cm. After 24 hours, the cells
were stimulated with IFN-g (100 or 500 U/mL) for the
Interferon-g phosphorylates STAT1 and suppressesadditional 20 hours and then pulsed with [3H]-thymidine
[3H]-thymidine incorporationfor 4 hours. Tetrachloric acid (TCA)-precipitable counts
were determined for each sample. Rat mesangial cells responded to IFN-g as expected,
which was shown by the appearance of phosphorylated
Transfer of anti-STAT1 antibody into rMCs STAT1 in whole cell lysates (Fig. 2A). Phosphorylated
by electroporation STAT1 was detected in IFN-g–treated nuclear extracts
that originally did not contain STAT1 (Fig. 1C). TheseWe electroinjected anti-STAT1 antibody according to
the method described elsewhere [16, 17] with minor mod- findings suggested that STAT1 was phosphorylated in
cytosol and that the phosphorylated STAT1 translocatedification. Briefly, rMCs were harvested and centrifuged
at 800 r.p.m. for five minutes. The cells were washed to the nucleus (Fig. 2A). IFN-g suppressed [3H]-thymi-
dine incorporation in a dose-dependent manner at con-once in Ca- and Mg-free PBS and then resuspended in
potassium-rich PBS. The cell suspension was transferred centrations of 10, 100, and 500 U/mL (Fig. 2B). There
were significant differences between control and IFN-gto an electroporation chamber containing monoclonal
antibody against STAT1 at a final concentration of 10 groups (*), between IFN-g (10 U/mL) and IFN-g (100
U/mL; **), and between IFN-g (10 U/mL) and IFN-gmg/mL and exposed to a single brief electric pulse with
a field strength of 750 V/cm. The cells were allowed to re- (500 U/mL; **P , 0.01). We infer from these data that
of all the signaling pathways activated by IFN-g, STAT1main in the chamber for two minutes and then plated in
RPMI media supplemented with 20% fetal bovine serum is associated with the IFN-g–induced suppressive effect
on rMC proliferation. The causal relationship between(FBS). After 24 hours, the cells were stimulated with
IFN-g (100 U/mL) for 20 hours and then pulsed with STAT1 activation and suppression of rMC proliferation
was examined in the following experiments.[3H]-thymidine for 4 hours. TCA-precipitable counts
were determined for each sample.
Activated STAT1 caused suppression of
rMC proliferationStatistical analysis
Experiments were performed in triplicate in each ex- We performed in situ b-galactosidase assay in order to
ascertain the introduction of ectopic DNA into culturedperiment (Fig. 2B) or in duplicate (Figs. 4 and 5). Com-
parisons were made with Fisher’s Protected Least Sig- rMCs by electroporation (Fig. 3A). Transcription effi-
ciency of the plasmid coding b-galactosidase was 17%.nificant Difference (Figs. 2B, 4, and 5). A P value of ,
0.05 (Figs. 4 and 5) or a P , 0.01 (Fig. 2B) was considered Overexpression of STAT1 protein was ascertained by
Western blotting (Fig. 3B). To demonstrate our hypothe-significant.
sis that STAT1 is responsible for the IFN-g–induced
suppressive effect on rMC proliferation, IFN-g–acti-
RESULTS
vated (100 and 500 U/mL) STAT1 signaling was en-
rMCs contain JAK1, JAK2, and STAT1 hanced by overexpressing wild-type STAT1 cDNA, and
then the STAT1 signaling was suppressed by dominant-We adopted IFN-g for the stimulation of the JAK-
STAT pathway. Of all of the JAK and STAT isoforms, negative STAT1 cDNA (Fig. 4). There were significant
differences between control transfected with empty vec-IFN-g is known to use JAK1 and JAK2 and to phosphor-
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Fig. 1. Presence of Janus kinases (JAK1 and JAK2) and signal trans-
ducers and activators of transcription (STAT1) in rat mesangial cells
(rMCs). rMCs were incubated with or without interferon-g (IFN-g; 100
U/mL) for 15 minutes at 378C (A and B). Ten micrograms of whole
cell lysates or nuclear extracts were electrophoresed and analyzed with
antibodies against JAK1, JAK2, and STAT1. Blocking peptides for
JAK1, JAK2, and STAT1 were also incubated with respective antibod-
ies. Abbreviations are: cont, control (medium only); IFN, interferon-g;
whole, whole cell lysates of untreated cells; nuclear, nuclear extracts of
untreated cells.
tor and the other groups (*) and between wild-type (R602T) STAT1 reversed IFN-g–induced suppression.
The recovery of [3H]-thymidine incorporation attainedSTAT1 and dominant-negative STAT1s (Y701F and
R602T; **P , 0.05). Transfection of wild-type STAT1 via disruption of intrinsic STAT1 activity by dominant-
negative STAT1s was observed to the same extent in thedecreased [3H]-thymidine incorporation, whereas that
of tyrosine-mutated (Y701F) or SH2 domain-mutated electroinjection experiment using anti-STAT1 antibody
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Fig. 2. (A) IFN-g phosphorylates STAT1, leading to translocation to the nucleus. (B) IFN-g suppresses mesangial cell proliferation. (A) rMCs
were incubated with or without IFN-g (100 U/mL for nuclear extracts and 500 U/mL for whole cell lysates) for 15 minutes at 378C, and 10 mg of
whole cell lysates or nuclear extracts were electrophoresed and analyzed with antibody against either STAT1 or Tyr (701)-phosphorylated STAT1.
The left upper two lanes show that STAT1 is phosphorylated by IFN-g as expected in Figure 1, and the right upper two lanes show that Tyr (701)-
phosphorylated STAT1 translocates to the nucleus. The left half of the lower panel shows the presence of STAT1 under IFN-g-stimulated and
-unstimulated conditions, and the right half of the lower panel shows the appearance of STAT1 in nuclear extracts of IFN-stimulated cells. (B)
rMCs cultured onto 24-well plates were incubated with increasing concentrations of IFN-g (10, 100, and 500 U/mL, respectively) for 20 hours;
thereafter, cells were subject to further incubation for four hours with [3H]-thymidine, and TCA-precipitable counts were determined. Control,
109104 6 7296 cpm; IFN (10 U/mL), 81545 6 3789 cpm; IFN (100 U/mL), 68256 6 5094 cpm; IFN (500 U/mL), 64980 6 5691 cpm. The data are
expressed as mean 6 SD (N 5 4). There were significant differences between control and IFN groups (*) and between IFN (10 U/mL) and other
IFN groups (**). Abbreviations are: control, medium only; IFN, interferon-g; whole, whole cell lysates; nuclear, nuclear extracts; TCA, tetrachloric
acid.
(Fig. 5). These data demonstrate that the IFN-g–induced probably caused by cell-type specificity, ligand specific-
suppression of rMC proliferation is mediated, at least in ity, and the complexity of signal integrity.
part, through the activated STAT1. As for cell-type specificity and ligand specificity, the
inhibition of STAT1 or STAT3 abolishes the prolifera-
tive effect of angiotensin II in vascular smooth muscleDISCUSSION
cells [11]. On the other hand, antiproliferative activity
Many cytokines that are associated with cellular prolif- of IFN-g is enhanced in NIH 3T3 cells by the specific
eration, such as PDGF, angiotensin II, erythropoietin,
inhibition of tyrosine dephosphorylation of STAT1, ulti-IFN-a, and IFN-g, activate JAKs, and STATs [9, 11, 12,
mately resulting in the constitutive phosphorylation on15, 23, 28–34]. PDGF in particular induces mesangial
Tyr (701) residue and the prolonged activation of STAT1cell proliferation and is believed to play an important
[21]. Furthermore, the growth inhibition induced by epi-role for progression of renal dysfunction in chronic glo-
dermal growth factor, IFN-a, and IFN-g requires STAT1merulonephritis [22, 35–40]. Angiotensin II has a pro-
activation in U3A cells, mouse embryonic fibroblasts,found effect on proliferation of vascular smooth muscle
and A431 cells [18, 19].cells [41] and may be a cause of benign nephrosclerosis
As for the complexity of signal integrity, PDGF acti-[42], in concert with high blood pressure itself. However,
vates STAT1 and stimulates proliferation of vascularthe precise role of STAT1 in mesangial cell proliferation
smooth muscle cells in concert with MAP kinase cas-in chronic glomerulonephritis remains unclear, because
cades [11].activated STAT1 induces proliferation in some cell types
Treatment with IFN-g results in recruitment of JAK2and suppresses proliferation in others [11, 18, 19, 21].
These differences in the effects of activated STAT1 are into IFN-g receptor-JAK1 complex [43] and activates
Nakashima et al: STAT1 suppresses proliferation of mesangium2254
Fig. 3. (A) Introduction of b-galactosidase expression plasmid into rMCs by electroporation. (B) The presence of overexpressed STAT1 protein
in rMCs electroporated with wild-type STAT1. (A) The b-galactosidase expression plasmid (30 mg) was electroporated into rMCs. After 24 hours,
the cells were subject to in situ staining for b-galactosidase. The figure shown is representative of three independent experiments. (B) Wild-type
STAT1 plasmid was electroporated into rMCs. Whole cell lysates were made after 24 hours. Twenty micrograms of the lysates were analyzed by
Western blotting against STAT1.
Fig. 4. (A) [3H]-thymidine incorporation is enhanced by electroporated wild-type STAT1 and reversed by Tyr-mutated (Y701F) STAT1 or SH2-
mutated (R602T) STAT1 in the presence of 100 U/mL (A) or 500 U/mL (B) of IFN-g. (A and B) The plasmids containing cDNA for wild-type
STAT1, Tyr-mutated STAT1 (Y701F), or SH2-mutated (R602T) STAT1 (20 mg of each) were cotransfected with b-galactosidase expression
plasmid (5 mg) into rMCs by electroporation. In control cells, the same amount of empty vector as that of STAT1 was cotransfected with
b-galactosidase plasmid. After 24 hours, cells were stimulated with IFN-g (100 or 500 U/mL) for 20 hours, followed by further incubation with
[3H]-thymidine for 4 hours. TCA-precipitable counts were determined for each sample: control, 100%; STAT1, WT, 90 6 2.3%; STAT1, Y701F,
110 6 9.6%; STAT1, R602T, 110 6 0.58% for IFN-g (100 U/mL, N 5 3) and cont, 100%; STAT1, WT, 82 6 5.2%; STAT1, Y701F, 110 6 15%;
STAT1, R602T, 132 6 11% for IFN-g (500 U/mL, N 5 4). The data are shown as mean 6 SEM and are expressed as a percentage of control.
Abbreviations are: control, medium only; IFN, interferon-g; TCA, tetrachloric acid.
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intracellular STAT1 and blocked dimerization. Our re-
sults met this expectation and thus supported the authen-
ticity of the data.
Although there is a possibility that endogenous
STAT1 plays a rate-limiting role in the suppressive effect
of IFN-g, our data show that overexpressed STAT1
strengthens the effect. This suggests that the STAT1-
binding promoter region (g-activated site) is not satu-
rated with phosphorylated STAT1 caused either by
partial phosphorylation of all the existing STAT1 or to
inadequate amounts of STAT1 in cytosol. If there are
inadequate amounts of STAT1 in cytosol, then increased
amounts of STAT1 as a substrate of JAK1 and JAK2 give
rise to more phosphorylated STAT1, thereby resulting in
the enhanced effect of IFN-g, which is consistent with
our data.
Fig. 5. Electroinjected anti-STAT1 antibody inhibits antiproliferative We first demonstrated that activated STAT1 sup-
effect of IFN-g on mesangial cell proliferation. The cell suspension
pressed mesangial cell proliferation. Together with find-was put into an electroporation chamber in the presence of either
monoclonal antibody against STAT1 (10 mg/mL) or nonimmunized ings of previous reports, our findings suggest that mesan-
mouse IgG for control (10 mg/mL) and was exposed to a single brief gial cell proliferation is positively regulated by MAP
electric pulse. Control mesangial cells or cells electroinjected with anti-
kinase cascade [11] and negatively regulated by STAT1STAT1 antibody were incubated with IFN-g (100 U/mL) for 20 hours,
followed by further incubation with [3H]-thymidine for 4 hours. TCA- signaling, and furthermore, that the predominant effect
precipitable counts were determined for each sample: cont, 100%; anti- of PDGF and angiotensin II is the activation of MAP
STAT1, 115.6 6 6.7% (N 5 5). The data are shown as mean 6 SD kinase cascade, which results in a net effect of prolifera-and are expressed as percentage of cont. There was significant difference
tion. Our hypothesis on the dual regulation of prolifera-between cont and anti-STAT1 (*P , 0.05). Abbreviations are: cont,
control (culture media with nonimmunized mouse IgG); IFN, inter- tion is supported by bifunctional effects of IFN-g ob-
feron-g (100 U/mL); anti-STAT1, electroporated antibody against served in KG-1a cells, a cell line of acute myelocyticSTAT1; TCA, tetrachloric acid.
leukemia, and primary cultures of BM CD341 cells [44].
Marra, Choudhury, and Abboud found that IFN-g by
itself had very little effect on DNA synthesis in mesangial
cells and that pretreatment with IFN-g markedly potenti-solely STAT1 of all the STAT isoforms [23]. Therefore,
ated the DNA-binding activity of STAT1 in response toSTAT1 is the most important candidate to assess the
PDGF or epidermal growth factor [45]. This discrepancyrole of STATs in our settings. In the present study, we
between our results and Marra’s may be attributable tofound that under the switch-on condition of IFN-g signal-
the different concentrations of IFN-g, the species differ-ing, the effect of STAT1 was enhanced by transfection
ence of mesangial cells, differences in the mesangial cellof wild-type STAT1 and was suppressed by tyrosine-
character, which may reflect distinct basal [3H]-thymi-mutated (Y701F) STAT1, SH2 domain-mutated (R602T)
dine incorporation, and different concentrations of endo-STAT1, and electroinjected anti-STAT1 antibody. These
toxin that might be contained in the serum supplementedthree STAT1 plasmids and anti-STAT1 antibody fluctu-
to culture media.ated only the activity of STAT1 under the constant acti-
In conclusion, STAT1 activated by IFN-g inhibits pro-vation of JAK1 and JAK2. This strategy enables us to
liferation of cultured rMCs.assess the specific effect of STAT1 on cellular prolifera-
tion by separating STAT1 signaling from JAK1 and ACKNOWLEDGMENTS
JAK2.
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